PDGFR-Β expression in small cell lung cancer patients

Eric T. Shinohara, Adriana Gonzalez, Pierre P. Massion, Sandra J. Olson, Jeffrey M. Albert, Yu Shyr, David P. Carbone, David H. Johnson, Dennis E. Hallahan, Bo Lu

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Background: Platelet derived growth factor (PDGF) and PDGFR-β are expressed and have been found to have prognostic value in several human cancers. Data in non-small-cell cancer cell lines have suggested that PDGFR is a therapeutic target for drug development. In the current study PDGFR-β expression and prognostic value in small cell lung cancer (SCLC) was investigated. Methods and Materials: Paraffin-embedded tissue blocks from 53 patients with limited and extensive stage SCLC were obtained for immunohistochemical staining. Tumors from each patient were sampled 3 times and stained with PDGFR-β specific antibody. Patients were divided into low and high staining groups based on intensity. Results: There was high intensity PDGFR-β staining in 20 patients with SCLC. Another 29 expressed low intensity PDGFR-β staining, with only 4 patients showing no PDGFR-β staining. There was no statistically significant difference in 5 year overall survival between patients with low levels of PDGFR-β staining vs. those with high level staining SCLC tumors (p = 0.538). Conclusions: The present study found that the majority of SCLC patients express, at least, a low level of PDGF-β. However, the level of PDGFR-β expression was not a statistically significant predictor of 5 year overall survival in SCLC.

Original languageEnglish
Pages (from-to)431-437
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Issue number2
StatePublished - Feb 1 2007


  • Biomarker
  • Lung cancer
  • Platelet derived endothelial growth factor
  • Prognosis
  • STI571
  • Tissue array


Dive into the research topics of 'PDGFR-Β expression in small cell lung cancer patients'. Together they form a unique fingerprint.

Cite this